Synbio International is a pre-revenue shell company with two stated business ambitions: an AI-powered mental health screening tool and a direct-to-consumer nutraceutical supplement. The AI tool, called FDI, uses a smartphone camera to analyze a patient's face and screen for PTSD, drawing on both Western and traditional Eastern diagnostic techniques. The company has signed an MOU to evaluate the technology and plans a small feasibility study followed by a larger validation study, both contingent on funding. No product exists yet and no clinical validation has been completed. The nutraceutical business plans to sell an anti-anxiety dietary supplement called "Healing Force - Anxiety Relief" through TV infomercials, social media, and digital influencers, though no product has launched and no production has begun. The company has one employee — the CEO — generates zero revenue, and carries an accumulated deficit of ~$3.1M. Operations are funded through a convertible note facility, interest-free CEO loans, and an unused equity drawdown facility. The company was originally incorporated in 2002 as Natural Harmony Foods and was dormant for years before a new controlling shareholder pivoted it toward its current focus in 2023. The CEO previously founded Medibio, an ASX-listed AI mental health screening company, suggesting a similar strategic thesis underlies this venture.